Department of Internal Medicine, Faculty of Medicine, Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon.
Department of Urology, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium.
World J Urol. 2022 Apr;40(4):951-964. doi: 10.1007/s00345-021-03924-x. Epub 2022 Jan 7.
Urinary microbiota has been found to play a key role in numerous urological diseases. The aim of this systematic review is to depict the role of urinary microbiota in the pathogenesis, diagnosis, prognosis, and treatment of urological tumors, including bladder cancer (BCa), prostate cancer (PCa) and renal cell carcinoma (RCC).
A systematic PubMed and Scopus search was undergone from inception through June 2021 for studies investigating urinary microbiota alterations in urological tumors. Study selection followed the PRISMA statement. Phylum, family, genus and species of each bacterium in cancer patients and controls were recorded.
Twenty-one studies with 1194 patients (748 cancer patients and 446 controls) were included in our final analysis. Certain bacterial phylum, family, genus, and species were more predominant in each of BCa, PCa and RCC patients compared to controls. Abundance and specificity of urinary microbiota were prognosticators for: (1) recurrence, distinguishing recurrent from non-recurrent BCa, (2) disease stage, distinguishing non-muscle invasive from muscle invasive BCa, and (3) disease grade, distinguishing high- vs. low-grade PCa and BCa. Dietary, environmental and geographic patterns influenced urinary microbiota. Urinary microbiota of benign prostatic hyperplasia was different from PCa.
Urological cancer patients have an altered urinary microbiota compared to controls. This may predict recurrence, disease stage and disease grade of these tumors. Further prospective studies are needed to depict a potential influence on therapeutic outcomes.
尿液微生物群已被发现在许多泌尿科疾病中发挥关键作用。本系统评价的目的是描述尿液微生物群在泌尿科肿瘤（包括膀胱癌（BCa）、前列腺癌（PCa）和肾细胞癌（RCC））的发病机制、诊断、预后和治疗中的作用。
从成立到 2021 年 6 月，我们对研究尿液微生物群改变在泌尿科肿瘤中的作用的系统评价进行了 PubMed 和 Scopus 搜索。研究选择遵循 PRISMA 声明。记录癌症患者和对照组中每种细菌的门、科、属和种。
我们的最终分析纳入了 21 项研究，共 1194 名患者（748 名癌症患者和 446 名对照）。与对照组相比，某些细菌门、科、属和种在 BCa、PCa 和 RCC 患者中更为常见。尿液微生物群的丰度和特异性是：（1）复发，区分复发性和非复发性 BCa，（2）疾病分期，区分非肌肉浸润性和肌肉浸润性 BCa，（3）疾病分级，区分高分级和低分级 PCa 和 BCa 的预后指标。饮食、环境和地理模式影响尿液微生物群。良性前列腺增生的尿液微生物群与 PCa 不同。
与对照组相比，泌尿科癌症患者的尿液微生物群发生了改变。这可能预测这些肿瘤的复发、疾病分期和疾病分级。需要进一步的前瞻性研究来描述对治疗结果的潜在影响。
